Inhibrx, Inc., a La Jolla, CA-based clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, received a $40m investment from Viking Global Investors LP.
Inhibrx has received approximately $205m since inception, including raising $135m in investor equity and debt and receiving $70m in licensing and grant payments. Viking joined existing investors RA Capital, Lilly Asia Ventures, ArrowMark Partners, WuXi Biologics and Alexandria.
The company intends to use the funds to advance its pipeline, including its three clinical-stage programs with two additional programs expected to enter the clinic this year, and its proprietary sdAb platform.
Led by Mark Lappe, Chief Executive Officer, Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.
The company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform, , which enables the construction of molecules that contain multiple binding units with defined valency or multiple specificities. The pipeline is focused on oncology, orphan diseases and infectious diseases.